EP0622075A1 — Transdermal delivery of active drugs
Assigned to Hercon Laboratories Corp · Expires 1994-11-02 · 32y expired
What this patent protects
A transdermal delivery system is described, including a backing layer having coated thereon an active drug-containing adhesive layer which includes (a) an acrylic-based adhesive which is self-crosslinking at a temperature of from about 20°C to about 65°C and (b) an active drug. A…
USPTO Abstract
A transdermal delivery system is described, including a backing layer having coated thereon an active drug-containing adhesive layer which includes (a) an acrylic-based adhesive which is self-crosslinking at a temperature of from about 20°C to about 65°C and (b) an active drug. A method for manufacturing a transdermal delivery system is also described, including (A) mixing an active drug with an acrylic-based adhesive solution which is self-crosslinking at a temperature of from about 20°C to about 65°C to form an active drug-adhesive mixture, (B) forming a coating of the active drug-adhesive mixture on a backing layer, and (C) drying the coating to form an active drug-containing adhesive layer. Examples of the active drug include nitroglycerin and estradiol.
Drugs covered by this patent
- Estrace (ESTRADIOL) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.